Knockout of GPRC5a by the CRISPR/Cas9 system can suppress proliferation and migration ability and may promote chemotherapy drug sensitivity in PaCa cells. Here, GPRC5A is linked to permanent neonatal diabetes mellitus-pancreatic and cerebellar agenesis syndrome.